Drug Profile
Melphalan drug delivery system - Delcath Systems
Alternative Names: CHEMOSAT; CHEMOSAT® Hepatic Delivery System for Melphalan; CS-PHP-Melphalan; Generation Two CHEMOSAT Delivery System for Melphalan; Hepzato Kit; HEPZATO-KIT; Melblez Kit; melphalan hydrochloride for injection/hepatic delivery system; Melphalan/HDS; Melphalan/Hepatic Delivery SystemLatest Information Update: 06 Feb 2024
Price :
$50
*
At a glance
- Originator Yale University School of Medicine
- Developer Delcath Systems; Leiden University Medical Center
- Class Antineoplastics; Aromatic amino acids; Myeloablative agonists; Nitrogen mustard compounds; Small molecules
- Mechanism of Action Alkylating agents; DNA damage stimulants; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Liver metastases
- Phase II/III Cholangiocarcinoma
- Phase II Liver cancer
Most Recent Events
- 06 Feb 2024 The Centers for Medicare and Medicaid Services (CMS) issues a permanent and product-specific J-code (J9248) for HEPZATO, effective from April 1, 2024
- 16 Jan 2024 Launched for Liver metastases (In adults) in USA (Intrahepatic)
- 01 Sep 2023 Delcath Systems plans to launch melphalan drug delivery system for Liver metastases arising from Uveal melanoma (Metastatic disease) in USA (Intrahepatic, infusion) by the end of 2023